{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/attention-deficit-hyperactivity-disorder/prescribing-information/atomoxetine/","result":{"pageContext":{"chapter":{"id":"4cb27755-8a20-55e7-abf6-188f7ef4cc15","slug":"atomoxetine","fullItemName":"Atomoxetine","depth":2,"htmlHeader":"<!-- begin field 6c25f980-4794-4242-a1ab-7ff89172c57e --><h2>Atomoxetine</h2><!-- end field 6c25f980-4794-4242-a1ab-7ff89172c57e -->","summary":"","htmlStringContent":"<!-- begin item 53d1abd5-a22f-4281-9cb9-802393494568 --><!-- begin field d758f0b4-5b26-438d-ada7-317033fe86b7 --><ul><li>Atomoxetine is <em>always </em>initiated in secondary care by a specialist. However, treatment may be continued and <a class=\"topic-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/management/management/#managing-confirmed-adhd\">monitored</a> by a general practitioner under a shared-care protocol.</li></ul><!-- end field d758f0b4-5b26-438d-ada7-317033fe86b7 --><!-- end item 53d1abd5-a22f-4281-9cb9-802393494568 -->","topic":{"id":"58fdf356-8ba5-546f-8dc0-2f52caf10b0d","topicId":"634d93f6-99ac-40ea-821e-2886075c4f40","topicName":"Attention deficit hyperactivity disorder","slug":"attention-deficit-hyperactivity-disorder","lastRevised":"Last revised in January 2021","chapters":[{"id":"97f99690-0b45-5db9-91f6-a4ccf1441f55","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3288c19f-08ea-5db5-9fe3-2a19e4e9480e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"117c3288-2c4b-54a9-93a6-e73cfa827ea6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"05022ed2-5af8-5139-9aee-325340958ba7","slug":"changes","fullItemName":"Changes"},{"id":"280f9139-8e61-5232-b633-87792a692c21","slug":"update","fullItemName":"Update"}]},{"id":"7df3faa3-c76c-5513-8300-b8e6c29a6710","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd6487fd-840a-583c-9def-1b3fbf119433","slug":"goals","fullItemName":"Goals"},{"id":"7d672b8e-e109-5eee-9f6a-937dc8647595","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6ee4b93a-2830-5f51-9991-1c95ef010724","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f40bd230-c678-561c-9d40-5bc8424b3e61","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"473473fc-1cf7-5675-876d-9cf4806ca71c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b7ed8daa-37ed-5957-8040-2744764b2b9c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9199d39e-4690-591d-9e22-737af0484d8b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"60a29f8c-bc0e-5bb1-9846-a4ef0725acfb","slug":"definition","fullItemName":"Definition"},{"id":"0e5e3505-ad73-5fe3-889b-d803507818a4","slug":"causes","fullItemName":"Causes"},{"id":"f3cd314a-8d03-53ce-a0c0-924d345fc73e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b286aedf-f99c-5903-9289-953caa385920","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ab5906d5-d2b3-5bc3-bfcf-512c0aa8be1e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d3399591-ed2d-5c77-9855-2e0b917c37ae","slug":"when-to-suspect-adhd","fullItemName":"When to suspect ADHD"},{"id":"79f2001b-57c3-521d-a4b3-a30df47980b7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"2bfc757a-5a5f-5796-bd7d-b0b48edaa5fc","fullItemName":"Management","slug":"management","subChapters":[{"id":"0042040f-0d1c-5531-856f-e59d3ecbfe9f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c3622cf7-82a4-5194-ba3d-ee79d5dcc6b1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e54ebc77-0347-59b3-9363-2fa71e52a56d","slug":"methylphenidate","fullItemName":"Methylphenidate"},{"id":"4cb27755-8a20-55e7-abf6-188f7ef4cc15","slug":"atomoxetine","fullItemName":"Atomoxetine"},{"id":"cdfd970d-3454-539a-8119-612214e9ba0c","slug":"amfetamines","fullItemName":"Amfetamines"}]},{"id":"c30641a4-ca7b-5cc3-bd1a-68cb35616b7b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"114d2691-2ead-5200-a465-7a97d6ea302e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"42cd6093-4642-503a-aee2-abe24e0af20c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ebdae4e0-6a27-5f95-af59-4d19d02719c5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2dc4be40-cd79-5b84-940c-7d3b5ddf196d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b89b6177-f75f-51ac-b701-99a0ce4f254e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5c21ec37-f21e-535e-81a7-d99081cf961e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cdb8e542-54f7-55a2-9ef4-42e064fccfff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c3622cf7-82a4-5194-ba3d-ee79d5dcc6b1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e39040c1-6b6f-585f-be77-112d6c731409","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6a2de94c-b510-431a-99b7-dc74bf3670b8 --><h3>What adverse effects are associated with atomoxetine?</h3><!-- end field 6a2de94c-b510-431a-99b7-dc74bf3670b8 -->","summary":"","htmlStringContent":"<!-- begin item b0763b22-877b-48d9-9fc7-93863d1ab56d --><!-- begin field 3e23e5da-ee6b-4293-860c-0a358b307df9 --><ul><li><strong>The most common adverse effects of atomoxetine include:</strong><ul><li>Gastrointestinal effects such as anorexia, dry mouth, nausea, vomiting, abdominal pain, constipation, dyspepsia, and flatulence.</li><li>Cardiovascular effects such as palpitation, tachycardia, increased blood pressure, postural hypotension, and hot flushes.</li><li>Central nervous system effects such as sleep disturbance, dizziness, headache, fatigue, lethargy, drowsiness, irritability, tremor, and rigors.</li><li>Dermatological effects such as dermatitis, pruritus, and rash.</li><li>Other effects including sweating, weight changes, urinary retention, enuresis, prostatitis, sexual dysfunction, menstrual disturbances, and conjunctivitis.</li></ul></li><li><strong>Less common, but important adverse effects include</strong>:<ul><li><strong>Suicidal ideation </strong>— patients and carers should be aware of the risk and should be vigilant for any change in behaviour, suicidal thoughts, agitation, aggression, emotional lability, or depression.</li><li><strong>Hepatic disorders </strong>— patients and carers should be aware of the risk and should be advised on the symptoms (abdominal pain, unexplained nausea, malaise, dark urine, or jaundice), suggesting liver damage, and encouraged to seek prompt medical help if this occurs.</li><li><strong>Very rarely, angle-closure glaucoma.</strong></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">BNF 75, 2018</a>] </p><!-- end field 3e23e5da-ee6b-4293-860c-0a358b307df9 --><!-- end item b0763b22-877b-48d9-9fc7-93863d1ab56d -->","subChapters":[]},{"id":"be88a83d-59c3-5473-8dea-429ffb21a53a","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field 75c92a12-2007-4ffd-bb93-a693d33ff113 --><h3>What key interactions are associated with atomoxetine?</h3><!-- end field 75c92a12-2007-4ffd-bb93-a693d33ff113 -->","summary":"","htmlStringContent":"<!-- begin item 9ce788d6-dcf4-4190-80ef-ea3cdb85d648 --><!-- begin field a23a753e-72ca-4494-9a82-c00bea7abe84 --><ul><li><strong>Monoamine oxidase inhibitors (MAOIs) </strong>— do not prescribe an MAOI to a person taking atomoxetine. Be aware that atomoxetine should not be used for at least 14 days after stopping treatment with an MAOI, and treatment with an MAOI should not be initiated within 14 days after stopping atomoxetine. Concurrent use of two or more serotonergic drugs may increase the risk of serotonin syndrome and symptoms similar to neuroleptic malignant syndrome.</li><li><strong>The following drugs increase the risk of ventricular arrhythmias and concurrent use with atomoxetine should be avoided </strong>(atomoxetine is associated with QT interval prolongation):<ul><li>Methadone (dosage above 100mg).</li><li>Disopyramide.</li><li>Nasal decongestants.</li><li>Amiodarone and sotalol.</li><li>Moxifloxacin.</li><li>Venlafaxine, mirtazapine, tricyclic antidepressants, and selective serotonin reuptake inhibitors</li><li>Mefloquine.</li><li>Antipsychotics such as haloperidol and pimozide.</li><li>Diuretics — the risk of ventricular arrhythmias are increased with diuretics that cause hypokalaemia.</li></ul></li><li><strong>Terbinafine </strong>— theoretically inhibits the cytochrome P450 enzyme and therefore increases the effect of atomoxetine. It is advised to start at a low dose and slowly titrate the dose when concurrent treatment with atomoxetine is indicated.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">BNF 75, 2018</a>] </p><!-- end field a23a753e-72ca-4494-9a82-c00bea7abe84 --><!-- end item 9ce788d6-dcf4-4190-80ef-ea3cdb85d648 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}